Can Posttransarterial Chemoembolization Volumetric Oil Deposition on Computed Tomography Predict Treatment Response on Magnetic Resonance Imaging in Leiomyosarcoma Metastases to the Liver?

J Comput Assist Tomogr. 2022 May-Jun;46(3):327-332. doi: 10.1097/RCT.0000000000001294. Epub 2022 Apr 8.

Abstract

Objective: To predict early tumor response to transarterial chemoembolization (TACE) based on volumetric oil deposition on posttreatment computed tomography (CT) in patients with leiomyosarcoma liver metastases.

Methods: This retrospective lesion-by-lesion based study included 32 lesions. The volumetric percent enhancing tumor on pre-TACE and 1-month post-TACE venous phase magnetic resonance imaging (MRI), and the percent oil deposition on CT 1 day after TACE were calculated. The predicted post-TACE enhanced percentage was computed by subtracting percent oil deposition from baseline percent enhanced.

Results: Mean percentage of viable tumor on pre-TACE MRI was 90.6% ± 9.3%. Mean oil deposition was calculated as 51.4% ± 26.2%. Mean percentage of measured residual tumor enhancement 1 month after TACE was 58.3% ± 27%, which correlates with predicted enhancement percentage of 43.9% ± 25.1% (r = 0.72, P < 0.001). A threshold of 35.5% for enhancement reduction was determined to predict tumor response with an accuracy of 78.1%.

Conclusion: Volumetric oil deposition on CT can predict residual enhancement on post-TACE MRI.

MeSH terms

  • Carcinoma, Hepatocellular* / therapy
  • Chemoembolization, Therapeutic* / methods
  • Humans
  • Leiomyosarcoma* / diagnostic imaging
  • Leiomyosarcoma* / therapy
  • Liver Neoplasms* / diagnostic imaging
  • Liver Neoplasms* / pathology
  • Liver Neoplasms* / therapy
  • Magnetic Resonance Imaging / methods
  • Retrospective Studies
  • Tomography, X-Ray Computed / methods
  • Treatment Outcome